Napsin A Rabbit Polyclonal Antibody
Specialties: Cytopathology Pulmonary Pathology
Napsin is a pepsin-like aspartic proteinase in the A1 clan of the AA clade of proteinases.1-3 Napsin A is involved in processing propeptide pulmonary surfactant protein B (proSP-B) in the lung.4 In normal, benign tissue, Napsin A is expressed in type II pneumocytes of the lung and proximal tubules of the kidney. Napsin A is a useful marker for lung adenocarcinoma.1-3, 5-8 The polyclonal Napsin A antibody exhibits cross reactivity with a number of non-pulmonary carcinomas such as colorectal carcinoma and renal cell carcinoma.9 Due to this cross reactivity, this product is not recommended to be used for differentiation between pulmonary and colorectal adenocarcinomas.
- Jagirdar, Jaishree. "Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung." Archives of pathology & laboratory medicine vol. 132,3 (2008): 384-96.
- Bishop, Justin A et al. "Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma." Human pathology vol. 41,1 (2010): 20-5.
- Rawlings ND and Salvesen GS. Handbook of Proteolytic Enzymes Volume 1. 3rd Edition. Academic Press. 2013; p.69-71.
- Brasch, Frank et al. "Involvement of napsin A in the C- and N-terminal processing of surfactant protein B in type-II pneumocytes of the human lung." The Journal of biological chemistry vol. 278,49 (2003): 49006-14.
- Dejmek, Annika et al. "Napsin A (TA02) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma cells in pleural effusions." Diagnostic cytopathology vol. 35,8 (2007): 493-7.
- Inamura, Kentaro et al. "Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas." The American journal of surgical pathology vol. 29,5 (2005): 660-5.
- Ye, Jiqing et al. "Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung." Applied immunohistochemistry & molecular morphology : AIMM vol. 19,4 (2011): 313-7.
- Mukhopadhyay, Sanjay, and Anna-Luise A Katzenstein. "Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6." The American journal of surgical pathology vol. 35,1 (2011): 15-25.
- Mukhopadhyay, Sanjay, and Anna-Luise A Katzenstein. "Comparison of monoclonal napsin A, polyclonal napsin A, and TTF-1 for determining lung origin in metastatic adenocarcinomas." American journal of clinical pathology vol. 138,5 (2012): 703-11.
Specifications
- Reactivity: paraffin
- Control: Lung Adenocarcinoma (Cytoplasmic); Kidney (Cytoplasmic)
- Dilution Range: 1:100-1:500 *
Package Inserts
IFU
- IVD Rev. 5.0 (CMC35217050)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
0.1 mL concentrate | 352A-74 |
0.5 mL concentrate | 352A-75 |
1.0 mL concentrate | 352A-76 |
1.0 mL predilute ready-to-use | 352A-77 |
7.0 mL predilute ready-to-use | 352A-78 |
For in vitro diagnostic (IVD) use in Canada
0.1 mL concentrate | 352A-74 |
0.5 mL concentrate | 352A-75 |
1.0 mL concentrate | 352A-76 |
1.0 mL predilute ready-to-use | 352A-77 |
7.0 mL predilute ready-to-use | 352A-78 |
For in vitro diagnostic (IVD) use in Europe
0.1 mL concentrate | 352A-74 |
0.5 mL concentrate | 352A-75 |
1.0 mL concentrate | 352A-76 |
1.0 mL predilute ready-to-use | 352A-77 |
7.0 mL predilute ready-to-use | 352A-78 |
For research use only (RUO) in Japan
0.1 mL concentrate (RUO) | 352A-74-RUO |
0.5 mL concentrate (RUO) | 352A-75-RUO |
1.0 mL concentrate (RUO) | 352A-76-RUO |
1.0 mL predilute ready-to-use (RUO) | 352A-77-RUO |
7.0 mL predilute ready-to-use (RUO) | 352A-78-RUO |
To request information on this product in additional countries, please click the button below.